SUMMARY New England Deaconess Hospital rats implanted with a pheochromocytoma P259 became hypertensive and showed high concentrations of plasma dopamine (42.0 ± 14.6 ng/ml) and norepinephrine (45.7 ± 8.4 ng/ml). However, the norepinephrine content of several peripheral tissues of these rats did not differ from those of the New England Deaconess Hospital control rats, and their dopamine content, although slightly higher, was much lower than would have been expected from the plasma dopamine levels. Methylation by catechol-O-methyltransferase did not appear to play a major role in the inactivation of tissue catecholamines since there were no noticeable increases of normetanephrine or 3-methoxytyramine in the tissues of the rats with pheochromocytoma. There was also no increase in conjugated dopamine, in either the sulfate or glucuronide form, in the plasma or tissue of the hypertensive rats, although injection of i.-dopa induced a large increase in dopamine sulfate in the plasma and urine of these rats. This finding indicated that, although their sulfoconjugation mechanism was intact and not affected by the pheochromocytoma, it did not participate in the metabolism of dopamine released by the tumor into the blood. On the other hand, plasma and urine of tumorbearing rats exhibited abnormally high concentrations of homovanillic acid, the main metabolite of dopamine resulting from monoamine oxidase action. In contrast to the control rats, intravenous infusion of free dopamine in rats with pheochromocytoma had no effect on plasma free dopamine levels but increased homovanillic acid levels considerably. The present data underline the important role of monoamine oxidase in the removal of excessive quantities of catecholamines released by the tumor in New England Deaconess Hospital rats with the pheochromocytoma implant. (Hypertension 8: 94l>-946, 1986) KEY WORDS • catecholamines • pheochromocytoma sulfoconjugation • monoamine oxidase activity storage • metabolism P HEOCHROMOCYTOMAS constantly secrete large quantities of catecholamines (CA) into the circulation, raising plasma CA to levels much higher than those in normal subjects.' 2 Nevertheless, in many patients with pheochromocytoma the blood pressure (BP) usually remains normal or less elevated than would be expected from the high level of plasma CA. Some studies indicate that the mechanism From the Laboratory of the Autonomic Nervous System (N.T. ' Buu, O. Kuchel),
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PHEOCHROMOCYTOMA AND TISSUE CATECHOLAMINES/fiuw et al.
esting to know how rat peripheral nervous tissues handle both the CA released continuously in large quantities by the tumor and any additional infusion of a large amount of CA, corresponding to a paroxysmal release in patients.
We have assayed the CA and their metabolites in several tissues in NEDH rats with a pheochromocytoma implant and in NEDH controls. Since we have previously shown in the rat that glucuronidation is a major metabolic pathway 10 but that sulfoconjugation, the major form of conjugation in humans," also becomes important when large quantities of DA are present, 12 we also determined both forms of conjugated CA in tissues, plasma, and urine of the two groups of rats, before and after an injection of L-dopa. Finally, we compared the fate of infused DA in NEDH rats with and without a pheochromocytoma implant.
Materials and Methods
Male NEDH rats, sham-operated or implanted with a P259 tumor, were received from the Cancer Research Institute of the New England Deaconess Hospital (Boston, MA, USA) approximately 2 months after birth and 6 days after the tumor implantation. They were housed in conventional animal facilities and given Purina rat chow (St. Louis, MO, US A) and water ad libitum. The rats were observed regularly for tumor growth. Once a week they were weighed and had their blood taken, under light ether anesthesia, through the tail vein for CA measurement.
Three days before the experiment, when the plasma NE and DA had risen to levels similar to those previously described, 7 we initiated a 24-hour urine collection, measured the BP, and took a final blood sample as described below.
Urine Collection
The rats were housed individually in metabolic cages 24 hours before the urine collection began. Urine was collected for 24 hours in a tube containing 100 /x\ of concentrated perchloric acid. The total volume was recorded, and the pH of the sample was measured and, if necessary, brought below 4 by the addition of perchloric acid. Aliquots were kept in plastic tubes and stored frozen at -8 0°C .
Blood Pressure Measurements
Arterial BP was taken by a Statham blood pressure transducer (Oxnard, CA, USA) through a catheter previously implanted under sodium pentobarbital (30 mg/kg) anesthesia into the carotid artery. The rats were free to move within the cage during the BP recording.
Blood and Tissue Sampling
One day after the BP measurement, 2 ml of blood was taken through the same carotid catheter in an icecold tube previously rinsed with a heparin solution (1000 U/ml) and containing 30 fi\ of 10% glutathione solution. After centrifugation, the plasma was separated and stored frozen at -8 0°C .
Rats were killed by decapitation, and the different tissues (heart, spleen, adrenal, lung, and liver) were quickly placed on ice and frozen in dry ice. The brains were dissected along the demarcations described by Glowinski and Iversen, 13 and the hypothalamus and brainstem were removed.
L-Dopa Treatment
The NEDH rats with and without a pheochromocytoma implant were implanted with a catheter in the carotid artery for blood sampling. One day after the operation, they were injected intraperitoneally with either saline or L-dopa (100 mg/kg, dissolved in 1 ml of 0.9% saline) and were housed in individual metabolic cages for urine collection. One hour after the injection, 1 ml of blood was withdrawn for analysis of CA. In a previous study, 12 we found that blood sampled 1 hour after L-dopa administration contained the highest concentrations of DA and DA sulfate. Urine was collected for 6 hours in tubes containing perchloric acid (20 /JL\) as described. The total volume was then measured, and the urine samples were stored frozen.
Dopamine Infusion
Rats anesthetized under sodium pentobarbital (30 mg/kg) had catheters implanted into the carotid artery and the jugular vein. Fifteen minutes after the operation and while the rats were under anesthesia, 1 ml of blood was withdrawn through the carotid artery and DA was infused at a rate of 0.03 ml/min for 45 minutes by means of a Harvard pump (Millis, MA, USA). The concentration of DA was such that its rate of infusion was 250 /xg/kg/hr. Immediately after the infusion, 1 ml of blood was withdrawn and the rat was killed by decapitation. The kidney and the heart were removed and stored frozen at -80°C until analysis.
Sample Treatment
Plasma was deproteinized with 3 M perchloric acid to which 1% ethylene glycol bisQ3-aminoethyl ether)-Nflfl' A'-tetraacetic acid had been added so that the final acid concentration was 0.3 M. The acid extract was separated from the proteins after centrifugation at 4°C and 9000 g for 10 minutes. In general, urine was diluted 50 times with 0.1 M perchloric acid containing 1% ethylenediaminetetraacetic acid.
Tissues were weighed and then homogenized in 10 volumes of 0.1 M perchloric acid. The homogenate was centrifuged for 10 minutes at 10,000 g, and the clear supernatant was separated for analysis of CA and their metabolites.
Measurement of Free and Conjugated Catecholamines
Free CA in the plasma and urine tissues were measured by the radioenzymatic methods previously described.
14 This method involves the O-methylation of the CA by catechol-O-methyltransferase with (5)- and epinephrine values. Sulfoconjugated CA were hydrolyzed by sulfatase (from Aerobacter aerogenes; Sigma, St. Louis, MO, USA), and glucuronoconjugated CA was hydrolyzed by bovine liver /3-glucuronidase (Ketodase, 5000 U/ml; Warner Lambert, Morris Plain, NJ, USA). The procedures of hydrolysis and measurement of conjugated CA have been described in detail. 10 ' " The difference between the total value obtained after either mode of hydrolysis and the value of the unconjugated fraction constitutes the quantity of conjugated CA in the sample.
Tissue CA were measured, before and after hydrolysis, after prior adsorption on acid-washed alumina, 16 as previously described. 15 
Other Measurements
The metabolites of CA were measured by high-performance liquid chromatography with electrochemical detection. The method of isolation of normetanephrine (NMN) and 3-methoxytyramine (3-MT) and the chromatographic conditions used for their measurement have been described. 17 Dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) also were measured by high-performance liquid chromatography after passage through a Sephadex column as described by Westerink and Korf. 18 The high-performance liquid chromatography system uses a Waters M-45 high pressure pump (Milford, MA, USA) to deliver the mobile phase through a Bondapak C, g reverse-phase column (Chromatography Science, Mount-Royal, Quebec, Canada). The column eluate was monitored by an amperometric detector (LC 4A; BAS, Lafayette, IN, USA) using a glassy carbon electrode set at an oxidation potential of 0.8V versus an Ag/HgCl reference electrode. The oxidation current was registered by a data processor (Model 3392A; Hewlett Packard, Palo Alto, CA, USA).
Statistical Analysis
Student's two-tailed t test was used when values between two groups of rats were compared. Ap value of less than 0.05 was considered statistically significant. Table 1 presents the concentrations of CA and conjugated CA in the plasma of NEDH rats with pheochromocytoma implants and their controls. In agreement with earlier findings by Manger et al., 7 rats with the tumor implants showed extremely high plasma concentrations of free DA and NE. Despite the very high level of free DA, DA sulfate concentrations were not detectable and the concentrations of DA glucuronide were similar to those in the NEDH control rats. Plasma free NE in the NEDH rats with pheochromocytoma was slightly higher than free DA, but neither NE sulfate nor NE glucuronide was detectable. We have previously reported little or no NE glucuronide in rat plasma." Values are means ± SEM. NEDH = New England Deaconess Hospital; DA = dopamine; ND = not detectable; NE = norepinephrine; HVA = homovanillic acid; DOPAC = dihydroxyphenylacetic acid; 3-MT = 3-methoxytyramine; NMN = normetanephrine.
Results
•Epinephrine also was detected in the plasma, but the values were not reported herein because they may be cross-contaminated (see Methods) by the larger quantities of NE.
tSignificantly different from control values. Table 2 shows tissue concentrations of free CA. The results for the tumor tissue confirm the predominance of DA and NE in this type of pheochromocytoma (P259). Although detected in the tumor and plasma, epinephrine concentrations, obtained by the radioenzymatic method, were not reported in this study because of possible cross-contamination (see Methods) by the much larger quantities of NE. Despite the large quantities of DA and NE secreted into the circulation (see Table 1 ), NE was not significantly higher in the tissues of the rats with pheochromocytoma, while the increase of DA, though statistically significant (except for the lung and liver), was small. These results are in agreement with those previously published. 20 Neither DA nor NE was elevated in the hypothalamus and brainstem of rats with pheochromocytoma, which indicates that the effect of the tumor on levels of CA was confined to the peripheral nervous system. Table 3 shows the quantities of free and conjugated CA excreted in the urine of NEDH rats with pheochromocytoma and controls. The catecholamine content of the urine samples reflects those found in the plasma (i.e., a large excess of NE and DA in the tumor-bearing rat and little or no DA sulfate in either group of rats). Urinary levels of DA glucuronides did not differ between the two groups.
hi contrast to the conjugated CA, metabolites of CA, resulting from the action of catechol-O-methyltransferase and monoamine oxidase (MAO; illustrated for DA in Figure 1 ) increased considerably in the urine of tumor-bearing rats ( Table 4 ). The largest increases were seen with HVA and DOPAC, which were, respectively, 80 and 30 times higher than in the control Heart (ng/g; n = 6) Kidney (ng/g; n = 7) Spleen (ng/g; n = 6) Adrenal Qxg/pair; n = 6) Hypothalamus (ng/g; n = 5) Brainstem (ng/g; n = 5) Lung (ng/g; n = 3) Liver (ng/g; n = 3)
Values are means ± SEM. Pheo = pheochromocytoma. Numbers in parentheses indicate number of tissues analyzed; ng/g indicates quantity in nanograms per gram of wet tissue.
*Epinephrine was detected in the tumor tissue, but the values were not reported herein because of possible crosscontamination from the much larger quantities of norepinephrine (see Methods).
tSignificantly different from control values. rat; this finding indicates that MAO plays the major role in the inactivation of DA released from the tumor. The concentrations of 3-MT and NMN, the methylated products of DA and NE, were 20 times higher than the control values, indicating that catechol-O-methyltransferase also participates in the inactivation process. The absence of a metanephrine increase is consistent with the finding that the tumor does not secrete epinephrine. 21 That a portion of the urinary metabolites originated in the tumor was indicated by the finding of significant amounts of NMN, 3-MT, DOPAC, and HVA in the tumor (Table 5 ). The concentration of 3-MT was approximately twice as high as that of HVA, which suggests that catechol-O-methyltransferase is more active than MAO in metabolizing DA in this tissue. In view of the high plasma NE and DA concentrations in these rats, it was totally unexpected that their tissue concentrations of DA sulfate, 3-MT, DOPAC, HVA, and NMN should be undetectable in most cases or, when detectable, not different from levels in the corresponding control rats ( Table 5 ).
The absence of DA sulfate in the plasma, urine, and tissues of the tumor-bearing rats prompted us to determine whether the sulfoconjugation mechanism is normal in these rats. To this end, we injected L-dopa into the rats to observe their response to an increase of DA. Such a treatment in Sprague-Dawley rats has been previously shown to increase plasma and urine DA sulfate considerably. 12 The results (Table 6) showed that L-dopa treatment indeed increased plasma and urinary DA sulfate considerably in NEDH rats, suggesting that the sulfoconjugation mechanism in these rats Table 1 for other abbreviations.
is as active as that in Sprague-Dawley rats and, if anything, more active in the presence of the tumor implant.
Infusion of DA into the NEDH rats with pheochromocytoma produced an unexpected result (Figure 2) . After a 45-minute infusion, plasma free DA in the NEDH control rat was markedly increased, but the same infusion in NEDH rats with pheochromocytoma had no effect on the basal plasma DA level. There was,
FIGURE 2. Increases or decreases in plasma concentration of free dopamine (DA), dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) in four New England Deaconess Hospital (NEDH) control rats and six rats with pheochromocytoma (PHEO) implant after DA infusion (250 ng/kg/hrfor 45 minutes). The values represent the difference between concentrations in blood sampled I minute before the infusion and blood collected immediately (<30 seconds) after the infusion. Blood was withdrawn through a previously implanted catheter.
however, a huge increase in HVA concentration, significantly more pronounced than that in the control rats.
Infusion of DA led to an increase in DA in the heart and kidney tissues of the NEDH control rats and the NEDH rats with pheochromocytoma. Although the DA increase in the rats with pheochromocytoma did not differ significantly from that observed in the NEDH control rats, there was a marked difference in their HVA response: tumor-bearing rats showed a much higher increase in HVA concentrations than did their controls (Figure 3) . Surprisingly, there was no detectable increase in DA sulfate or DA glucuronide in the plasma and tissues of the infused rats, which indicates that conjugation of infused DA may be different from conjugation of DA newly generated from L-dopa. Values are means ± SEM. Plasma was collected 60 minutes after L-dopa or saline injection. Urine was collected during a 6-hour period after L-dopa or saline injection. DA = dopamine; ND = not detectable. 
Discussion
This study on NEDH rats with pheochromocytoma implants produced a surprising result regarding the storage of CA in the tumor-bearing rats: despite the large quantities of NE and DA released by the tumor, as indicated by the very high NE and DA plasma levels, the concentrations of NE in the peripheral tissues of the rat were no different from those of the NEDH control rats, and the difference in DA concentrations, although statistically significant, was small.
Our data provide no explanation for the preferential increase in tissue DA levels in the rats with pheochromocytoma, since plasma concentrations of DA and NE were approximately equal. It is possible that NE was more actively metabolized by MAO, although there has been no evidence to date for a preferential action of this enzyme on one catecholamine as opposed to another.
That a rapid metabolism of CA in the pheochromocytoma rats may partly explain their lack of increase in the tissue was suggested by the finding that infusion of pharmacological doses of free DA into the bloodstream of rats with pheochromocytoma did not increase plasma DA, in contrast to results obtained in NEDH control rats (see Figure 2) , whereas there was a huge increase of plasma HVA (much larger than that in controls), which clearly demonstrated that metabolism by MAO is significantly enhanced in the tumorbearing rats. This is also supported by the high basal levels of plasma HVA and DOPAC in these rats. However, the activation of the metabolic process in the NEDH pheochromocytoma rats seems to be restricted to MAO activity; sulfoconjugation, which plays a predominant role in the metabolism of plasma DA in humans," dogs, 22 and Sprague-Dawley rats injected with L-dopa, 12 did not contribute significantly to the inactivation of the huge quantities of DA released by the tumor. Neither did glucuronidation, the other form of conjugation in the rat."
The relationship between sulfoconjugation and glucuronidation in the rat remains unknown. Studies with the perfused rat liver indicated that saturation or inhibition of one process usually led to increased activity for the other. 23 However, the absence of any increase in either DA sulfate or DA glucuronide in the tumorbearing rats seems to indicate that neither process was saturated. This was confirmed by the finding that the rats with a pheochromocytoma implant showed a marked increase in plasma DA sulfate following L-dopa injection, exhibiting a normal sulfoconjugation response, similar to that found in NEDH control rats or in Sprague-Dawley rats. 12 This normal response also excludes the possibility that phenolsulfotransferase activity was inhibited by the large amounts of CA secreted by the tumor. On the other hand, it is possible that the DA released by the tumor into the circulation was unable to gain access to the phenolsulfotransferase, which, as suggested by previous results, 24 is mainly localized in extraneuronal tissues.
In addition, catechol-O-methyltransferase, also an extraneuronal enzyme, 23 did not play a major role in the inactivation of DA and NE in the peripheral tissues, since NMN and 3-MT levels were undetectable or, when detectable, were no different from those of control NEDH rats. Because 3-MT and NMN, respectively, are good markers of DA and NE release, 26 the lack of change in their tissue levels suggests that the large quantities of DA and NE in the plasma were not, taken up by the nervous tissue and released into extraneuronal spaces.
In conclusion, our results show that the large quantities of DA and NE released into the plasma by the pheochromocytoma implant were not stored in notable amounts in peripheral tissues of the NEDH rat. The results with the catecholamine metabolites suggested that neither phenosulfotransferase nor catechol-Omethyltransferase contributed significantly to the metabolism of the released CA, although the sulfoconjugation mechanism remained normal. On the other hand, metabolism by MAO was strongly enhanced in the rats with pheochromocytoma, and this may serve as a defense mechanism in the hypertensive pheochromocytoma rats, protecting the tissue from the large quantities of CA released in the plasma.
